A recent study published in Ophthalmology has found that the combination of polihexanide (PHMB) and propamidine is a safe and effective treatment for the rare eye infection known as Acanthamoeba keratitis (AK).

The study, conducted by John K.G. Dart, D.M., from Moorfields Eye Hospital in London, compared two treatment options for AK: topical PHMB 0.02 percent + propamidine 0.1 percent and PHMB 0.08 percent + placebo. The analysis included 127 patients.

The results showed that both treatment options had a high medical cure rate within 12 months, with 86.6 percent for PHMB 0.02 percent + propamidine and 86.7 percent for PHMB 0.08 percent. The noninferiority requirement was met for PHMB 0.08 percent, indicating its effectiveness. Secondary outcomes for both groups were similar, with a median best-corrected visual acuity of 20/20 and an overall treatment failure rate of 13.4 percent, of which 6.3 percent required therapeutic keratoplasty. Importantly, no serious drug-related adverse events were reported.

Dart expressed optimism about the findings, stating, “We hope that our new robust findings with polihexanide 0.08 percent will be a game changer for AK treatment, by improving access and the consistency of treatment, addressing currently unmet patient needs.”

It’s worth noting that several authors involved in the study disclosed ties to pharmaceutical companies, including SIFI S.p.A., which sponsored and funded the trial.

This research provides valuable insights into the treatment of Acanthamoeba keratitis and may lead to improved access and consistency in treating this rare eye infection.

Source: HealthDay News

Link to the full article: [Abstract/Full Text](https://www.aaojournal.org/article/S0161-6420(23)00710-8/fulltext)

Copyright © 2023 HealthDay. All rights reserved.

Categorized in: